Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$79.53 USD

79.53
136,834

-1.83 (-2.25%)

Updated Jun 10, 2024 04:00 PM ET

After-Market: $79.72 +0.19 (0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for LGND

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Ligand Pharmaceuticals Incorporated [LGND]

Reports for Purchase

Showing records 521 - 540 ( 718 total )

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 521

05/14/2015

Company Report

Pages: 7

Price: 24.95

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 522

05/12/2015

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 523

05/11/2015

Company Report

Pages: 8

1Q15 Results, Pipeline Expands and Partners Cranking; Target to $127

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 524

05/05/2015

Company Report

Pages: 7

Price: 24.95

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 525

03/31/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 526

03/30/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 527

03/30/2015

Company Report

Pages: 4

Kyprolis Priority Review and CEMelphalan Stability; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 528

03/16/2015

Industry Report

Pages: 6

Healthcare Recap: Opportunities and Catalyst Focus Name of Game Going Forward

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 529

03/02/2015

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 530

03/02/2015

Company Report

Pages: 4

Kyprolis Trumps Velcade; Superior Efficacy Should Translate Into Sales

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 531

02/09/2015

Company Report

Pages: 6

Growth Continues and Company is Shopping; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 532

02/09/2015

Daily Note

Pages: 4

Discontinuation of Coverage of Ligand Pharmaceuticals

Provider: Brinson Patrick Securities Corporation

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 533

02/04/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 534

02/04/2015

Company Report

Pages: 7

Setting Up Potential Next Rounds of Promacta Growth; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 535

02/03/2015

Company Report

Pages: 6

Continued Asset Monetization Bolstering Future Growth; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 536

01/28/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 537

01/28/2015

Company Report

Pages: 7

Kyprolis Numbers and Likely Footprint Expansion; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 538

01/27/2015

Company Report

Pages: 9

Highly Confident about 2015 Overall Business Strategy

Provider: Brinson Patrick Securities Corporation

Analyst: JAMES C

Price: 25.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 539

01/09/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Ligand Pharmaceuticals Incorporated

Industry: Medical - Biomedical and Genetics

Record: 540

01/09/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party